Palivizumab

Indications

Palivizumab is used for: Indicated for the prevention of serious, lower respiratory tract disease, caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease, Passive immunisation of infants against, lower respiratory tract infections

Adult Dose

Not indicated

Child Dose

Intramuscular Child: RSV Prophylaxis Indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease 15 mg/kg IM q1Month during RSV season with first dose administered prior to the season

Renal Dose

Administration

Contra Indications

Hypersensitivity to palivizumab or other humanised monoclonal antibodies.

Precautions

Patient w/ thrombocytopenia or other coagulation disorder, moderate to severe acute infection or febrile illness. Not intended for use in adult. Pregnancy and lactation.

Pregnancy-Lactation

Pregnancy Not indicated for use in females of reproductive potential Lactation Not indicated for use in females of reproductive potential Lactation: no studies done

Interactions

Side Effects

Side effects of Palivizumab : >10% Fever (27%) Rash (26%) 1-10% Antibody formation (1-2%) <1% Pain Hernia SGOT increased Cough Bronchiolitis Pneumonia Dyspnea Sinusitis Apnea Thrombocytopenia Failure to thrive Diarrhea Vomiting Conjunctivitis Eczema Anemia Angioedema Flu syndrome

Mode of Action

Palivizumab is a recombinant humanised monoclonal antibody which targets the surface glycoprotein, responsible for recognition and entry into the cell on the resp syncytial virus (RSV).